Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Enforcement Directorate (ED)
Assam Floods
Bharat Bandh
Defence Ministry
Agnipath Scheme
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / At least half of Indians have COVID-19 antibodies: Credit Suisse
India

At least half of Indians have COVID-19 antibodies: Credit Suisse

At least half of Indians have COVID-19 antibodies: Credit Suisse
Written by Ramya Patelkhana
Jun 09, 2021, 11:03 pm 3 min read
At least half of Indians have COVID-19 antibodies: Credit Suisse
Credits:

Leading financial services company Credit Suisse revealed at least half of the Indian population, as per its estimates, would now have developed antibodies against COVID-19 caused by the novel coronavirus. Neelkanth Mishra, Co-head of Asia Pacific Strategy and India Equity Strategist, Credit Suisse, said many Indian districts would have moved beyond the herd immunity phase even for the highly infectious Delta variant. Here's more.

Details
About 77 crore Indians would have already developed COVID-19 antibodies

Speaking to The Print, Mishra said as per Credit Suisse's estimates about 77 crore people in India would have already developed COVID-19 antibodies—a little more than half of India's population. This high seroprevalence of COVID-19 antibodies and the ongoing relaxation of lockdown and other restrictions across many states may even lead to a "steep rebound" of the gross domestic product (GDP) in the country.

Estimation
Estimates based on hypotheses; national seroprevalence survey recommended: Mishra

Moreover, Mishra said these estimates are based only on hypotheses and not the real-time status. "We recommend a granular and nationwide seroprevalence study," he said. Credit Suisse's estimates are based on the Indian Council of Medical Research's third serological survey that showed by mid-December 2020, 21.4% of Indians were infected and the infection-to-case ratio was 28x—one crore cases and 28 crore people with antibodies.

Information
Positive test ratios higher in second wave

Mishra noted there were higher positive test ratios in the second COVID-19 wave compared to the first wave and hence ratio of those with antibodies in this wave would at least be the same as the first wave and "possibly even higher."

Conservative model
Mishra explains how 77 crore Indians would have developed antibodies

Estimating the number of people with antibodies, Mishra said, "If, to be conservative, one model with 20x, we are at about 60 crore infections (28 crore in the first wave and 32 crore in the second wave) in addition to 17 crore people with at least one jab of the vaccine." So, about 77 crore people in the country would now have developed antibodies.

Explanation
It's estimated many districts would be well beyond herd immunity

Mishra said, "From this (estimated 77 crore with antibodies) you take out say 5 crore for double-counting—such as people infected twice or thrice or overlaps between those with infections and those with vaccination—and you still have around half the population with antibodies." "If you use 30x, many districts would be well beyond herd immunity even for the much more infectious Delta variant," he added.

On GDP
A steep rebound of GDP in India likely: Mishra

Mishra also spoke about the GDP, saying it should witness a significant improvement as lockdown restrictions are being lifted gradually—the rebound would be "steep." "If active cases continue to fall...steeply...relaxation of lockdowns is likely to be faster. While we need to be on the lookout for another surge...as activities resume, the likely high seroprevalence should reduce the risk of that occurrence," he said.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Ramya Patelkhana
Ramya Patelkhana
Mail
Ramya Patelkhana is a senior editor at NewsBytes. She has nearly seven years of experience in digital journalism and has previously worked with India News and Authint Media. She has a Bachelor's degree in Journalism and Mass Communication from the IK Gujral Punjab Technical University, Kapurthala, and an advanced diploma in Media Studies from IPW, New Delhi.
Latest
Credit Suisse
Coronavirus
COVID-19
Coronavirus Cases In India
Related
Latest
'JugJugg Jeeyo' box office: Film earns Rs. 12cr+ on Saturday
'JugJugg Jeeyo' box office: Film earns Rs. 12cr+ on Saturday Entertainment
Thiomargarita magnifica: What do we know about world's largest bacterium
Thiomargarita magnifica: What do we know about world's largest bacterium Technology
Stefanos Tsitsipas wins Mallorca Championships: His stats on grass courts
Stefanos Tsitsipas wins Mallorca Championships: His stats on grass courts Sports
Ranbir wraps shooting for Luv Ranjan directorial co-starring Shraddha: Report
Ranbir wraps shooting for Luv Ranjan directorial co-starring Shraddha: Report Entertainment
Karnataka: Man throws birthday party for dog with 4,000 guests
Karnataka: Man throws birthday party for dog with 4,000 guests India
Credit Suisse
Where are the toppers of CAT (IIM) 2011-15 now?
Where are the toppers of CAT (IIM) 2011-15 now? India
Now, you can transfer money between mobile wallets, courtesy RBI
Now, you can transfer money between mobile wallets, courtesy RBI Business
Where are the toppers of CAT (IIM) 2011-15 now?
Where are the toppers of CAT (IIM) 2011-15 now? India
Where are the toppers of CAT (IIM) 2011-15 now?
Where are the toppers of CAT (IIM) 2011-15 now? India
40mn JioPhones sold so far, 21mn in Q1 2018: Report
40mn JioPhones sold so far, 21mn in Q1 2018: Report Business
More News
Coronavirus
How long does immunity last after COVID-19?
How long does immunity last after COVID-19? Technology
#NewsBytesExplainer: Why experts believe 4th COVID-19 wave is not coming
#NewsBytesExplainer: Why experts believe 4th COVID-19 wave is not coming India
COVID-19: India logs 7,584 fresh cases, 24 more fatalities
COVID-19: India logs 7,584 fresh cases, 24 more fatalities India
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
More News
COVID-19
ENG vs IND: Rohit Sharma tests positive for COVID-19
ENG vs IND: Rohit Sharma tests positive for COVID-19 Sports
5 train travel hacks for a comfortable experience
5 train travel hacks for a comfortable experience Lifestyle
COVID-19 vaccines prevented 42L deaths in India in 2021: Report
COVID-19 vaccines prevented 42L deaths in India in 2021: Report India
COVID-19: India logs 17,336 new cases, highest in 4 months
COVID-19: India logs 17,336 new cases, highest in 4 months India
Average salary of Indian CEO is over Rs. 11cr: Deloitte
Average salary of Indian CEO is over Rs. 11cr: Deloitte Business
More News
Coronavirus Cases In India
COVID-19: India logs 13,313 fresh cases, 38 more fatalities
COVID-19: India logs 13,313 fresh cases, 38 more fatalities India
COVID-19: India logs 12,249 fresh cases, 13 more fatalities
COVID-19: India logs 12,249 fresh cases, 13 more fatalities India
COVID-19: India logs 9,923 fresh cases, 17 more fatalities
COVID-19: India logs 9,923 fresh cases, 17 more fatalities India
COVID-19: India logs 12,781 fresh cases, 18 more fatalities
COVID-19: India logs 12,781 fresh cases, 18 more fatalities India
COVID-19: India reports 13,216 new cases, 23 more deaths
COVID-19: India reports 13,216 new cases, 23 more deaths India
More News
Related
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA World
COVID-19: The R-naught of coronavirus in India surges to 1.01
COVID-19: The R-naught of coronavirus in India surges to 1.01 India
Kerala has least COVID-19 antibodies: ICMR's national serosurvey
Kerala has least COVID-19 antibodies: ICMR's national serosurvey India
COVID-19: Everything to know about Delta, Delta-Plus, Kappa, Lambda variants
COVID-19: Everything to know about Delta, Delta-Plus, Kappa, Lambda variants India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022